Empagliflozin, Dulaglutide, and Atorvastatin during 1st weeks of pregnancy: a case report

Abstract

Among women of reproductive age, type 2 diabetes mellitus (T2DM) is becoming increasingly common, raising the risk of miscarriage, birth defects, and infant mortality. Optimal glycemic control and maintaining a healthy weight can decrease the chances of experiencing these negative outcomes. Insufficient research has been conducted on dulaglutide, empagliflozin and atorvastatin to determine their impact on causing birth defects or miscarriages in pregnancy; hence, their use in pregnancy have not been approved by the Food and Drug Administration (FDA). The initial three months of pregnancy (1-13 weeks) are typically regarded as the most dangerous time. A case of 35-year-old woman who has had type 2 diabetes mellitus for two years. Prior to becoming pregnant, she was taking atorvastatin 10 mg daily, empagliflozin 10 mg daily, and dulaglutide 12.5 mg/week. At eight weeks gestation, she was seen for the first time in the diabetic clinic. Because dulaglutide, empagliflozin, and atorvastatin are not approved during pregnancy, they were stopped, and she was started on basal-bolus insulin therapy with dosing titration. The patient had an elective cesarean section at 38 weeks. The male newborn had normal weight for his age. There were no congenital defects or neonatal morbidities observed. There were no complications for the mother. Even though the outcome of this pregnancy is normal, the information presented here might be useful for exploring this issue further.